Targeting RNA helicase DHX33 blocks Ras‐driven lung tumorigenesis in vivo

Ras has been found to be mutated in 30% of non‐small cell lung cancers, and its mutation has been regarded as a causal factor underlying tumorigenesis. However, no successful medicine has been developed so far to inhibit Ras for lung cancer treatment. We have previously identified DHX33 as a Ras dow...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xingshun, Feng, Weimin, Peng, Cheng, Chen, Shiyun, Ji, Hongbin, Zhong, Hanbing, Ge, Wei, Zhang, Yandong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Carcinogenesis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540983/
https://www.ncbi.nlm.nih.gov/pubmed/32767810
http://dx.doi.org/10.1111/cas.14601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540983/
https://www.ncbi.nlm.nih.gov/pubmed/32767810
http://dx.doi.org/10.1111/cas.14601

Ejemplares similares